I love these lists from amazing oncs like @ErikaHamilton9. Looking forward to @hoperugo’s report on Keynote-B49 (pembro + chemo in HR+ MBC), esp since pembro + cape seems to be working for me (minus that pesky ILD).
Register for SABCS now! We need advocates there to be part of the conversations, remind the scientists and clinicians statistically significant is different than meaningful to people, and hold their feet to the fire when they say “side effects are tolerable” 😝
Today is the last day to get the lowest registration rates for #SABCS26. Register now and join the global breast cancer community in San Antonio, Dec. 8–11. Visit https://t.co/198xE9nHRk to register.
@nlinmd@DFCI_BreastOnc Bispecifics, new targets, definitely new payloads, true “smart bomb” tech with fewer off target side effects, radioligands, nanotechnology, better biomarkers to determine tx and predict AEs, so many things!!
@drsarahsam Yes! And options in all subtypes beyond 3rd line (says someone on her 7th LOT with this drop in 27.29, but with new onset ILD so 1/2 of regimen is on pause). AND we need effective drugs with fewer AEs
here’s another timely finding that fits with this from @AMJohnston1315’s blog “A patient may spend every waking hour calculating whether the treatment is worth what it is taking from them”: tumor marker results came in today.
Today the side effects are worth it.
This blog from @AMJohnston1315 is so timely, as I’ve just been dx with ILD, a known side effect of immunotherapy, and am now dealing with all the 💩 that comes with the steroids to treat the ILD. “The willingness to endure suffering is not evidence that suffering does not exist.”
New blog post up, musings on Tolerability of the medication that is both keeping us alive and affecting every corner of that life: https://t.co/iFxY6q9bSb. #bcsm
@AMJohnston1315 It’s always something with MBC - my husband just had a tooth pulled and is snoring on one end of the sectional, so I’m hoping to get a nap in on the other end before he wakes up and I have to play nurse 😝
Breakthroughs happen because research is funded, prioritized, and demanded. For metastatic breast cancer, time matters. Research is urgent.
Give now and be part of meaningful progress in #MBCresearch. Click the link in our bio!
@LesleycStephen Right now I’m on pembrolizumab and that is probably what it’s from - small chance it’s infectious (although respiratory pathogen panel was negative) so on antibiotic too.
Meet Roxana Guerra, a speaker at METAvivor’s Stage IV Stampede & Summit 2026.
Roxana will join “Support Our Sisters: Building Peer-to-Peer Connections to Educate, Empower, and Expand Access” on October 5.
Meet Roxana: https://t.co/7pW7smPHzH
#METAvivor#StageIVStampede
@JaniceTNBCmets After several years when everything seemed to be HER2+, the pendulum seems to have swung to HR+, and it definitely needs to swing to TNBC. What we really need are multiple pendulums swinging at the same time and hitting all subtypes!
Join us for the first webinar of the 2026–2027 Metastatic Breast Cancer Forum Series, hosted by the EMBRACE Program at @DanaFarber!
📅 October 21, 2026| 10:30 a.m. – 1:00 p.m. ET
💻 Hosted Virtually, via Zoom
This webinar will be held in two parts:
• Welcome Session | 10:30 – 11:45 a.m. ET
• Breakout Sessions | Noon – 1 p.m. ET
Each breakout session will provide an opportunity to learn about treatment and research updates for each sub-type of #MetastaticBreastCancer.
This recurring monthly webinar series offers educational programs for adults living with metastatic breast cancer (#MBC), covering research updates, supportive care, and practical and logistical topics throughout the year.
For more information and registration, please visit: https://t.co/kOEv17jBsP
With October approaching, we want to make it easy to support METAvivor and metastatic breast cancer research.
The easiest and fastest way to give is online.
Every gift makes a difference.
Learn more: https://t.co/SG2m49OTkC
Donate now: https://t.co/T3iLG709Q9